Skip to main content
. 2021 May 13;23(10):1736–1749. doi: 10.1093/neuonc/noab111

Table 2.

Adverse Events

Adverse Event Grade Experimental Arm (N = 83) Standard Arm (N = 40)
Alopecia All grades 37 (45%) 19 (48%)
Grade 3-4 0 (0%) 0 (0%)
Anemia All grades 6 (7%) 0 (0%)
Grade 3-4 1 (1%) 0 (0%)
Anorexia All grades 25 (30%) 10 (25%)
Grade 3-4 1 (1%) 0 (0%)
Blurred vision All grades 16 (19%) 3 (8%)
Grade 3-4 1 (1%) 0 (0%)
Chills All grades 3 (4%) 1 (3%)
Grade 3-4 0 (0%) 0 (0%)
Constipation All grades 30 (36%) 15 (38%)
Grade 3-4 0 (0%) 0 (0%)
Dehydration All grades 9 (11%) 2 (5%)
Grade 3-4 0 (0%) 0 (0%)
Dermatitis radiation All grades 17 (20%) 8 (20%)
Grade 3-4 0 (0%) 0 (0%)
Diarrhea All grades 16 (19%) 5 (13%)
Grade 3-4 0 (0%) 2 (5%)
Dizziness All grades 15 (18%) 6 (15%)
Grade 3-4 0 (0%) 0 (0%)
Dry mouth All grades 12 (14%) 7 (18%)
Grade 3-4 0 (0%) 0 (0%)
Dysgeusia All grades 15 (18%) 7 (18%)
Grade 3-4 0 (0%) 0 (0%)
Dyspepsia All grades 10 (12%) 2 (5%)
Grade 3-4 1 (1%) 0 (0%)
Ear pain All grades 6 (7%) 1 (3%)
Grade 3-4 0 (0%) 0 (0%)
Edema limbs All grades 14 (17%) 4 (10%)
Grade 3-4 0 (0%) 1 (3%)
Fatigue All grades 67 (81%) 29 (73%)
Grade 3-4 6 (7%) 1 (3%)
Headache All grades 57 (69%) 20 (50%)
Grade 3-4 3 (4%) 1 (3%)
Insomnia All grades 31 (37%) 7 (18%)
Grade 3-4 0 (0%) 0 (0%)
Mucosal infection All grades 8 (10%) 3 (8%)
Grade 3-4 0 (0%) 0 (0%)
Nausea All grades 45 (54%) 17 (43%)
Grade 3-4 0 (0%) 0 (0%)
Vomiting All grades 12 (14%) 5 (13%)
Grade 3-4 0 (0%) 0 (0%)
Weight loss All grades 10 (12%) 3 (8%)
Grade 3-4 0 (0%) 0 (0%)